ABSTRACT
PURPOSE: The increase in the prevalence "long-term cancer survivor" (LCS) patients is expected to increase the cost of LCS care. The aim of this study was to obtain information that would allow to optimise the current model of health management in Spain to adapt it to one of efficient LCS patient care. METHODS: This qualitative study was carried out using Delphi methodology. An advisory committee defined the criteria for participation, select the panel of experts, prepare the questionnaire, interpret the results and draft the final report. RESULTS: 232 people took part in the study (48 oncologists). Absolute consensus was reached in three of the proposed sections: oncological epidemiology, training of health professionals and ICT functions. CONCLUSION: The role of primary care in the clinical management of LCS patients needs to be upgraded, coordination with the oncologist and hospital care is essential. The funding model needs to be adapted to determine the funding conditions for new drugs and technologies.
Subject(s)
Cancer Survivors , Models, Theoretical , Neoplasms/therapy , Delphi Technique , Humans , Medical Oncology/standards , SpainABSTRACT
The aim of this study to evaluate the efficacy of a home-based programme on clinical response, continuous positive airway pressure (CPAP) compliance and cost in a population of high pre-test probability of suffering obstructive sleep apnoea syndrome (OSAS). Patients were randomised into the following three groups. Group A: home respiratory polygraphy (RP) and home follow-up; group B: hospital polysomnography and hospital follow-up; and group C: home RP and hospital follow-up. Evaluation during 6 months included Epworth Sleepiness Scale (ESS), Functional Outcomes Sleep Questionnaire (FOSQ), and daily activity and symptom questionnaires. Compliance was assessed by memory cards (group A) and using an hourly counter (groups B and C). 66 patients were included (22 per branch), 83% were males, aged mean±sd 52±10 yrs, body mass index 34±7kg·m(-2), apnoea/hypopnoea index 43±20 h(-1), CPAP pressure 8±2 cmH(2)O, with no between-group differences. Clinical response showed an ESS of mean±sd 15±3 to 6±4, a FOSQ of 16±3 to 18±2, symptoms of 43±7 to 25±7, and activity of 37±11 to 25±8. At the end of the study, compliance was: group A 73%, group B 68% and group C 57%. The cost per patient was: group A 590±43, group B 894±11 and group C 644±93 (p<0.001). In conclusion, patients with a high initial probability of having OSAS can be diagnosed and treated in a home setting, with a high level of CPAP compliance and lower cost than using either a hospital-based approach or home RP/hospital follow-up.
Subject(s)
Ambulatory Care/methods , Continuous Positive Airway Pressure/methods , Home Care Services , Polysomnography , Sleep Apnea, Obstructive/diagnosis , Sleep Apnea, Obstructive/therapy , Adult , Continuous Positive Airway Pressure/nursing , Female , Follow-Up Studies , Humans , Male , Middle Aged , Patient Compliance , Polysomnography/nursing , Sleep Apnea, Obstructive/nursing , Surveys and QuestionnairesABSTRACT
BACKGROUND: Various methods have been described for safely performing fiberoptic bronchoscopy (FB) while applying non-invasive positive pressure ventilation (NIPPV) in patients with acute respiratory failure (ARF). OBJECTIVES: To evaluate the safety of a new method to perform FB in patients with ARF. METHODS: Patients with ARF in whom FB was indicated were studied. The primary end-point was a mean drop in oxygen saturation (S(a)O(2)) after the procedure. During nasal NIPPV, FB was performed via the mouth using a bite block sealed with an elastic glove finger allowing bronchoscope insertion. RESULTS: Thirty-five patients were included in the final study (63 ± 17 years, 74% men, P(a)O(2)/F(i)O(2) ratio 168 ± 63). A total of 35 bronchoaspirates, 21 protected brushings, 11 bronchoalveolar lavages and 8 bronchial biopsies were done. The cardiorespiratory variables at the start and end of FB were: S(a)O(2) 93 ± 3 to 94 ± 5%, heart rate 95 ± 17 to 99 ± 22 b.p.m. and respiratory rate 24 ± 11 to 25 ± 11 respirations/min. The lowest S(a)O(2) value reached during the procedure was 86 ± 3% and the maximal ETCO(2) rise was 41 ± 4 mm Hg. Leakage was <50 ml/s in 32 patients. The clinical course was favorable in 66%. Invasive ventilation was necessary in 11%, 5 ± 4 days after FB. Twelve patients (33%) died 3 ± 2 days after FB as a result of their underlying disease. CONCLUSIONS: The system allowed to perform FB safely in patients with ARF. Although there is a relatively high rate of intubation and invasive mechanical ventilation due to illness severity, there was no worsening of oxygenation or complications attributable to the procedure.
Subject(s)
Bronchoscopy/instrumentation , Respiratory Distress Syndrome/diagnosis , Adult , Aged , Aged, 80 and over , Female , Fiber Optic Technology , Humans , Male , Middle Aged , Prospective StudiesSubject(s)
Asthma/diagnosis , Lung/metabolism , Mast Cells/pathology , Mastocytosis, Systemic/diagnosis , Abdominal Pain , Acetates/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Asthma/complications , Asthma/physiopathology , Asthma/therapy , Budesonide/therapeutic use , Capillary Permeability/drug effects , Cough , Cyclopropanes , Diarrhea , Dyspnea , Female , Humans , Lung/drug effects , Lung/pathology , Mast Cells/drug effects , Mastocytosis, Systemic/complications , Mastocytosis, Systemic/physiopathology , Mastocytosis, Systemic/therapy , Middle Aged , Nedocromil/therapeutic use , Quinolines/therapeutic use , SulfidesABSTRACT
A 24-year-old Moroccan man was admitted to the hospital because of a tumor of the abdominal wall, fever, and purulent sputum. Imaging tests showed the presence of a pleural effusion and tumor in the right abdominal wall. The organized collection of liquid in the mass was contiguous with the thoracic collection and that of the subphrenic space. Thoracocentesis removed purulent material suggestive of empyema. Cultures and polymerase chain reaction (PCR) tests confirmed the diagnosis of tuberculous empyema. Empyema necessitatis refers to empyema that extends into the extrapleural space through a defect in the pleural surface. Various infectious etiologies may be responsible. Tuberculous empyema necessitatis is a rare complication of tuberculosis (TB); our case is even more unusual because this condition presented as an abdominal wall abcess and the patient was immunocompetent. His only predisposing factors were his country of origin, where there is a high prevalence of TB and the delay in diagnosis due to a lack of access to health care.
Subject(s)
Abdominal Wall/pathology , Abscess/microbiology , Empyema, Tuberculous/complications , Skin Diseases/pathology , Abdominal Wall/microbiology , Abscess/diagnostic imaging , Abscess/pathology , Adult , Empyema, Tuberculous/diagnosis , Humans , Immunocompetence , Male , Mycobacterium tuberculosis/isolation & purification , Paracentesis , Pleural Cavity/diagnostic imaging , Pleural Cavity/microbiology , Polymerase Chain Reaction , Radiography , Skin Diseases/microbiologyABSTRACT
No disponible
No disponible
Subject(s)
Female , Aged , Humans , Pneumonia/microbiology , Bordetella Infections/complications , Bordetella bronchiseptica/pathogenicity , Pulmonary Emphysema/complicationsABSTRACT
A new method is described for performing oral fiberoptic bronchoscopy during noninvasive ventilation through the nose. The technique was successfully applied in 2 patients suffering from acute respiratory failure. The bronchoscope was inserted through a glove finger fitted into a mouth guard. The system works as a valve and does not affect performance of the bronchoscopy procedure or the pressures administered during noninvasive ventilation. We conclude that the procedure has potential advantages over bronchoscopy through the nose and face masks or helmets, particularly for the management of secretions or in special clinical circumstances (hemoptysis or presence of foreign bodies). This method can be used to substitute for or complement other bronchoscopy techniques performed with other interfaces.
Subject(s)
Bronchoscopy/methods , Masks , Respiration, Artificial/methods , Respiratory Insufficiency/therapy , Acute Disease , Aged , Female , Fiber Optic Technology , Humans , Male , Middle AgedABSTRACT
Se describe un nuevo método para la realización de fibrobroncoscopia (FB) por vía bucal durante la administración de ventilación no invasiva por vía nasal, que se aplicó con éxito en 2 pacientes afectados de insuficiencia respiratoria aguda. La FB se realizó a través de una pieza de protección bucal a la que se adaptó un dedo de guante por dentro del cual se introdujo el fibrobroncoscopio. El sistema actúa como una válvula y no interfiere con las presiones administradas durante la ventilación no invasiva ni con los procedimientos broncoscópicos. Se concluye que el procedimiento presenta ventajas potenciales frente a la vía nasal por mascarilla facial o helmet, sobre todo en el manejo de secreciones o en circunstancias especiales (hemoptisis o cuerpo extraño), y permite alternar o complementar la FB practicada con otras interfaces
A new method is described for performing oral fiberoptic bronchoscopy during noninvasive ventilation through the nose. The technique was successfully applied in 2 patients suffering from acute respiratory failure. The bronchoscope was inserted through a glove finger fitted into a mouth guard. The system works as a valve and does not affect performance of the bronchoscopy procedure or the pressures administered during noninvasive ventilation. We conclude that the procedure has potential advantages over bronchoscopy through the nose and face masks or helmets, particularly for the management of secretions or in special clinical circumstances (hemoptysis or presence of foreign bodies). This method can be used to substitute for or complement other bronchoscopy techniques performed with other interfaces
Subject(s)
Male , Female , Aged , Middle Aged , Humans , Bronchoscopy/methods , Masks , Respiration, Artificial/methods , Respiratory Insufficiency/therapy , Acute Disease , Optical FibersABSTRACT
Three cases of thoracic actinomycosis are described, two associated to bronchial obstruction (foreign body and bronchogenic carcinoma) and one in a patient with empyema. The clinical and radiological manifestations and diagnostic criteria are reviewed and all published cases in the Spanish literature are thoroughly analyzed.
Subject(s)
Actinomycosis/diagnosis , Lung Diseases/microbiology , Adult , Aged , Humans , Lung Diseases/diagnosis , Male , Risk FactorsABSTRACT
Se describen tres casos de actinomicosis torácica, dos asociados a obstrucción bronquial (cuerpo extraño y carcinoma broncogénico) y uno en un paciente con empiema. Se revisan las manifestaciones clínico radiológicas de la misma, los criterios diagnósticos y se exponen de forma pormenorizada todos los casos publicados en la literatura española
Three cases of thoracic actinomicosis are described, two associated to bronchial obstruction (foreign body and bronchogenic carcinoma) and one in a patient with empiema. The clinical and radiological manifestations and diagnostic criteria are reviewed and all published cases in the Spanish literature are throughly analyzed
Subject(s)
Male , Female , Adult , Humans , Actinomycosis/diagnosis , Lung Diseases/microbiology , Risk Factors , Lung Diseases/diagnosisABSTRACT
No disponible
Subject(s)
Male , Middle Aged , Humans , Chondroma , Pneumonia , Bronchial NeoplasmsABSTRACT
Mitonafide was the first synthetized compound of a new series of 3-nitronaphthalimides with intercalative properties. A phase I study with a conventional escalation scheme was developed. The schedule of drug administration was a daily x 5 days by short (1 h) intravenous (i.v.) infusion, every 21 days. Thirty evaluable patients were treated at doses from 15.4 mg/m2/d x 5 days to 138.6 mg/m2/d x 5 days. The study was interrupted due to appearance of central nervous system toxicity in 5 patients treated at doses above 118 mg/m2 x 5 days. This toxicity consisted firstly of loss of memory in all patients. It was irreversible and progressed in 3 patients to disorientation and confusion, leading to dementia in one of them. This was considered to be dose-limiting toxicity, and since it appeared to be related to the administration schedule, no further studies with short i.v. infusions of mitonafide are recommended. A phase I study utilizing a more desirable administration schedule over longer periods of time is ongoing in other centers.